Jove
Visualize
Contact Us

Related Experiment Videos

Personalized medicine.

Kewal K Jain1

  • 1Jain PharmaBiotech, Bläsiring 7, CH-4057 Basel, Switzerland. jain@pharmabiotech.ch

Current Opinion in Molecular Therapeutics
|February 25, 2003
PubMed
Summary
This summary is machine-generated.

Personalized medicine uses pharmacogenetic and pharmacogenomic information to tailor treatments to individuals. This approach enhances therapy effectiveness and reduces drug development costs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personalized Immuno-Oncology.

Medical principles and practice : international journal of the Kuwait University, Health Science Centre·2020
Same author

An Overview of Drug Delivery Systems.

Methods in molecular biology (Clifton, N.J.)·2019
Same author

Role of Nanobiotechnology in Drug Delivery.

Methods in molecular biology (Clifton, N.J.)·2019
Same author

A Critical Overview of Targeted Therapies for Glioblastoma.

Frontiers in oncology·2018
Same author

Personalized neurology.

Personalized medicine·2018
Same author

Personalized Management of Cardiovascular Disorders.

Medical principles and practice : international journal of the Kuwait University, Health Science Centre·2017
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Biotechnology
  • Genomics
  • Pharmacology

Background:

  • Personalized medicine tailors treatments to individuals using genetic information.
  • Pharmacogenetics and pharmacogenomics are key to this approach.

Purpose of the Study:

  • Review the foundations of personalized medicine.
  • Examine its technologies, applications, and implications.

Main Methods:

  • Review of pharmacogenetic and pharmacogenomic information.
  • Discussion of technologies like SNP genotyping, haplotyping, gene expression studies, and proteomics.
  • Integration of molecular diagnostics with therapy and diagnosis.

Main Results:

  • Personalized medicine enables genotype-based patient selection for effective cancer therapy, avoiding non-responders and side effects.

Related Experiment Videos

  • Pharmacogenomics integration in clinical trials reduces failure rates and improves therapeutic safety and efficacy.
  • Personalized therapy is financially feasible, reducing drug development costs by shortening development cycles.

    • Conclusions:

    • Personalized medicine offers significant advantages, including improved patient outcomes and cost-effectiveness.
    • Challenges to its development exist but are being addressed.
    • Anticipated widespread adoption in medical practice.